WO2012016050A3 - Chemoradiotherapy for kras-mutant colorectal cancer - Google Patents
Chemoradiotherapy for kras-mutant colorectal cancer Download PDFInfo
- Publication number
- WO2012016050A3 WO2012016050A3 PCT/US2011/045735 US2011045735W WO2012016050A3 WO 2012016050 A3 WO2012016050 A3 WO 2012016050A3 US 2011045735 W US2011045735 W US 2011045735W WO 2012016050 A3 WO2012016050 A3 WO 2012016050A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- kras
- chemoradiotherapy
- colorectal cancer
- mutant colorectal
- mutant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
This invention relates to methods of treating KRAS-mutant cancers by administering a composition comprising Midostaurin (PKC-412), and methods for increasing the sensitivity of colorectal cancers to radiation, e.g., using Midostaurin (PKC-412) to radiosensitize colorectal cancers or cancer cells.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36848210P | 2010-07-28 | 2010-07-28 | |
| US61/368,482 | 2010-07-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2012016050A2 WO2012016050A2 (en) | 2012-02-02 |
| WO2012016050A3 true WO2012016050A3 (en) | 2012-05-24 |
Family
ID=45530722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2011/045735 Ceased WO2012016050A2 (en) | 2010-07-28 | 2011-07-28 | Chemoradiotherapy for kras-mutant colorectal cancer |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2012016050A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015041837A1 (en) | 2013-09-19 | 2015-03-26 | The Research Foundation For The State University Of New York | Methods and materials for treating diabetes or liver steatosis |
| JP2015096049A (en) * | 2013-11-15 | 2015-05-21 | 凸版印刷株式会社 | Method for predicting long-term efficacy of VEGF inhibitor |
| WO2016160590A1 (en) * | 2015-03-27 | 2016-10-06 | The Research Foundation For The State University Of New York | Methods and materials for treating cancer |
| CA2981138A1 (en) | 2015-03-27 | 2016-10-06 | The Research Foundation For The State University Of New York | Methods and materials for reducing amyloid beta levels within a mammal |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3325104A (en) * | 1963-07-15 | 1967-06-13 | Hartford Machine Screw | Fuel injection nozzle |
| US6543421B2 (en) * | 2000-03-21 | 2003-04-08 | Siemens Automotive Corporation | Fuel injector assembly for mounting a fuel injector to a fuel rail and permitting alignment of the fuel injector |
-
2011
- 2011-07-28 WO PCT/US2011/045735 patent/WO2012016050A2/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3325104A (en) * | 1963-07-15 | 1967-06-13 | Hartford Machine Screw | Fuel injection nozzle |
| US6543421B2 (en) * | 2000-03-21 | 2003-04-08 | Siemens Automotive Corporation | Fuel injector assembly for mounting a fuel injector to a fuel rail and permitting alignment of the fuel injector |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012016050A2 (en) | 2012-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2014018563A3 (en) | Methods for the treatment of cancer | |
| HK1199100A1 (en) | Methods and compositions for the treatment and diagnosis of colorectal cancer | |
| WO2011082266A3 (en) | Substituted heterocyclic compounds | |
| WO2011082270A3 (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
| WO2011082273A3 (en) | Substituted pyrrolo-aminopyrimidine compounds | |
| AU2016204376A1 (en) | MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer | |
| WO2011082267A3 (en) | Substituted triazolo-pyrazine compounds | |
| WO2012177844A3 (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
| WO2012048099A3 (en) | Nanoparticle-loaded cells | |
| MX370721B (en) | Novel compounds and compositions for targeting cancer stem cells. | |
| AU2010233994A8 (en) | Bispecific anti-ErbB-3/anti-c-Met antibodies | |
| WO2010111406A3 (en) | Purine derivatives useful as anti - cancer agents | |
| WO2014116833A3 (en) | Compositions and methods for detecting neoplasia | |
| HK1199290A1 (en) | Methods and compositions for the treatment and diagnosis of breast cancer | |
| WO2011123678A3 (en) | Substituted benzo-pyrido-triazolo-diazepine compounds | |
| WO2012103810A1 (en) | Certain chemical entities, compositions, and methods | |
| PH12015501088A1 (en) | Dimeric compounds | |
| WO2013106747A3 (en) | Methods and compositions for the treatment and diagnosis of thyroid cancer | |
| WO2012024350A3 (en) | Anti-cancer adenoviruses | |
| WO2011082268A3 (en) | Substituted naphthalenyl-pyrimidine compounds | |
| WO2013052108A3 (en) | Methods and compositions for the treatment and diagnosis of ovarian cancer | |
| WO2012016050A3 (en) | Chemoradiotherapy for kras-mutant colorectal cancer | |
| WO2012061342A3 (en) | Substituted benzo-imidazo-pyrido-diazepine compounds | |
| WO2012061012A3 (en) | 4-amino-2h-pyran-2-one analogs as anticancer agents | |
| PL2754441T3 (en) | Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11813188 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 11813188 Country of ref document: EP Kind code of ref document: A2 |